The evidence that GLP1R variants influence these traits across different ancestries without directly mediating behavioural changes through GLP1R suggests that GLP1RA therapies might be employed broadly in patients with type 2 diabetes and obesity, without undue concern for exacerbating mental health problems. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.